Moderna
Found 11 recent publications
Wall Street Ends Mixed as Boeing Wins USD 20B Defense Contract and AI Deals Drive Individual Stocks
Wall Street ended mixed as a volatile trading session was driven by major corporate news, including a USD 20 billion Boeing defense contract, a USD 1.2 billion AI deal for HPE, and a sharp rating downgrade for Moderna.
What will happen to Moderna stock after the surge? Analyzing 'overbought' stocks
The RSI indicator, used to identify 'overheated' stocks, signaled this week a series of stocks that surged rapidly—led by Moderna and Merck following a breakthrough in cancer vaccine development. What does this indicator mean, and why is it not necessarily a sell signal?
The surge on Wall Street, the losses of the short-sellers and the chance to prevent cancer: where are Moderna shares heading
The pharma stock that analysts bet against jumped by 177% in one day, causing billions in losses for short-sellers and forcing hedge funds to sell some of their best stocks. This happened following a successful cancer vaccine trial. But does it justify a $30 billion increase in value?
Not just Moderna: Morgan Stanley predicts Merck stock will soar
While Moderna grabbed headlines with a 177% jump, its partner Merck recorded its best day since 2009. Morgan Stanley has upgraded its recommendation, highlighting the company's potential beyond its flagship drug, despite the looming patent expiration.
Rami Levy invests 225 million shekels, while Max to pay tens of millions in compensation
Key economic stories of the week: Rami Levy invests 225 million shekels in a new project, Max to compensate businesses, Victory's profits jump 150%, Moderna shares soar on Wall Street, plus Amos Luzon's deal, chaos at Ben Gurion Airport, and Itay Levi's real estate move.
Drama on Wall Street: Liquidation of giant positions worth a billion dollars
An exceptionally stormy trading day ended in the US with a sharp turn in the bond market, an unusual jump in Bitcoin that led to a quick short squeeze, and dramatic news in a cancer vaccine trial.
Moderna recorded the sharpest stock increase in the S&P 500 index since 2008
Breaking an 18-year record: The success of clinical trials combining mRNA technology in the fight against cancer has led to an unprecedented surge in Moderna's stock. According to The Wall Street Journal, the company recorded the sharpest daily increase of any S&P 500 firm since 2008.
Breakthrough for Moderna and Merck: Promising Results in Advanced Melanoma Vaccine Trial
An experimental personalized cancer vaccine from Merck and Moderna has shown positive preliminary results in a Phase 3 trial. The combination therapy significantly reduced the risk of melanoma recurrence.
Breakthrough for Moderna and Merck: Promising results in advanced melanoma vaccine trial
An experimental personalized cancer vaccine for melanoma from Merck and Moderna has shown positive preliminary results in its first late-stage trial. The combination therapy significantly extended the time patients lived without recurrence.
Senior Health Ministry official on the new flu vaccine: "It is identical to the coronavirus vaccines" | Listen
Prof. Tal Brosh, Director of the Infectious Diseases Unit at Assuta Ashdod Hospital, explained on 103fm radio about the mRNA flu vaccine approved in the US: "In the coming season, it will certainly not be relevant."
After decades: A new flu vaccine has been approved that may change the rules of the game
The US Food and Drug Administration (FDA) has approved Moderna's Mfalusiva, the first seasonal flu vaccine based on mRNA technology. In a large-scale trial, the vaccine showed a 26.6% higher relative efficacy compared to a standard-dose flu vaccine.